Opaganib

$6 million upfront with up to approximately $13.4 million of potential aggregate gross proceeds upon the exercise in full of warrants 600万美元预付款，在认股权证全部行使时，潜在总收益最高可达约1,340万美元TEL AVIV, Israel & RALEIGH, N.C. 以色列特拉维夫 & 北卡罗来纳州罗利, ，June 18, 2026 2026年6月18日/PRNewswire/ -- /美通社/ --RedHill Biopharma Ltd. 红山生物制药有限公司(Nasdaq: （纳斯达克：RDHL RDHL) ('RedHill' or the 'Company'), a specialty biopharmaceutical company, today announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 8,571,429 American Depositary Shares ('ADSs') (or ADS equivalents in lieu thereof), each ADS representing ten thousand (10,000) ordinary shares of the Company, series A-1 warrants to purchase up to an aggregate of 8,571,429 ADSs and series A-2 warrants to purchase up to an aggregate of 8,571,429 ADSs, at a combined purchase price of $0.70 per ADS (or ADS equivalent in lieu thereof) and accompanying warrants in a private placement. )（“RedHill”或“公司”），一家专业生物制药公司，今日宣布已签订一项最终协议，以每股美国存托股份（“ADS”）（或替代的ADS等价物）0.70美元的合并购买价格，通过私募方式买卖总计8,571,429股美国存托股份（“ADS”）（或替代的ADS等价物），每份ADS代表公司一万股（10,000股）普通股，以及最多可购买总计8,571,429股ADS的A-1系列认股权证和最多可购买总计8,571,429股ADS的A-2系列认股权证。The Series A-1 warrants have an exercise price of $0.86 per ADS, are exercisable immediately and have a term of five years following the Effectiveness Date (as defined below), and the Series A-2 warrants have an exercise price of $0.70 per ADS, are exercisable immediately and have a term of 18 months following the Effectiveness Date. A-1系列认股权证的行权价格为每美国存托股份0.86美元，可立即行权，期限为生效日（定义见下文）起五年；A-2系列认股权证的行权价格为每美国存托股份0.70美元，可立即行权，期限为生效日起18个月。The private placement is expected to close on June 22, 2026, subject to the satisfaction of customary closing conditions.. 预计此次私募配售将于2026年6月22日完成，但须满足惯常的交割条件。H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. H.C. Wainwright & Co. 担任本次发行的独家配售代理。The gross proceeds to the Company from this offering are expected to be approximately $6 million, before deducting the placement agent's fees and other offering expenses payable by the Company. The potential additional gross proceeds to the Company from the series A-1 warrants and the series A-2 warrants, if fully exercised on a cash basis, will be approximately $13.4 million. 本公司从本次发行中获得的总收益预计约为600万美元，该金额未扣除配售代理费用及本公司应支付的其他发行费用。若A-1系列认股权证和A-2系列认股权证全部以现金方式行权，本公司可能获得的额外总收益将约为1,340万美元。No assurance can be given that any of the series warrants will be exercised, or that the Company will receive cash proceeds from the exercise of the series warrants.. 无法保证任何系列认股权证将被行权，也无法保证公司将从系列认股权证的行权中获得现金收益。The Company intends to use a portion of the net proceeds to support a potential strategic product acquisition and the balance for working capital, research and development and general corporate purposes. 本公司拟将部分净收益用于支持潜在的战略产品收购，其余部分用于营运资金、研发及一般公司用途。No definitive acquisition agreement has been executed, and any such transaction would remain subject to completion of definitive documentation, financing and other customary conditions. There can be no assurance that any such transaction will be completed. 尚未签署任何具有约束力的收购协议，且任何此类交易仍须以完成最终文件、融资及其他惯例条件为前提。无法保证任何此类交易将会完成。The securities described above were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the 'Securities Act'), and/or Regulation D promulgated thereunder and, along with the ordinary shares of the Company represented by ADSs underlying the warrants, have not been registered under the Securities Act or applicable state securities laws. 上述证券已根据经修订的《1933年证券法》（以下简称“《证券法》”）第4(a)(2)条以及/或据此颁布的D条例，以私募方式发行；且该等证券，连同由认股权证所对应的美股存托凭证（ADSs）所代表的公司普通股，均未根据《证券法》或适用的州证券法律进行注册。Accordingly, the securities issued in the private placement and ordinary shares of the Company represented by ADSs underlying the warrants may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. 因此，除非依据生效的注册声明或适用《证券法》及相关州证券法律中关于注册要求的豁免规定，否则不得在美国要约或出售私募发行的证券以及由认股权证所对应的美股存托凭证（ADS）所代表的公司普通股。Pursuant to a registration rights agreement with the investors, the Company has agreed to file a resale registration statement covering the securities described above (such date of effectiveness of the resale registration statement, the 'Effectiveness Date').. 根据与投资者签订的注册权协议，公司已同意提交一份涵盖上述证券的转售注册声明（该转售注册声明生效之日为“生效日”）。This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.. 本新闻稿不构成出售要约或购买要约的招揽，也不得在任何州或其他司法管辖区进行此类证券的销售，若在该等州或其他司法管辖区，在根据当地证券法完成注册或资格认定之前，此类要约、招揽或销售属违法。About RedHill Biopharma 关于红山生物制药RedHillBiopharma Ltd. (Nasdaq: RedHill Biopharma有限公司（纳斯达克：RDHL RDHL) is a specialty biopharmaceutical company primarily focused onU.S.development and commercialization of drugs for gastrointestinal diseases, infectious diseases and oncology.RedHillpromotes the FDA-approved gastrointestinal drug ）是一家专业生物制药公司，主要专注于胃肠道疾病、传染病和肿瘤药物的美国开发与商业化。RedHill 推广其获美国食品药品监督管理局（FDA）批准的胃肠道药物Talicia 塔利西亚® ®, ，for the treatment of 用于治疗Helicobacter pylori (H. pylori) 幽门螺杆菌（H. pylori）infection in adults 成人感染[1] [1], with a U.S. co-commercialization agreement with Cumberland Pharmaceuticals (Nasdaq: ，并与坎伯兰制药公司（纳斯达克股票代码：CPIX CPIX).RedHill'skey clinical late-stage development programs include: (i) ）。RedHill 的关键临床后期开发项目包括：(i)opaganib 奥帕加尼布(ABC294640), a first-in-class, orally administeredsphingosinekinase-2 (SPHK2) selective inhibitor with anti-inflammatory, antiviral, metabolic and anticancer activity, targeting multiple indications withU.S. government and academic collaborations intended for medical countermeasure development including for Ebola virus disease, radiation exposure indications such as GI-Acute Radiation Syndrome (GI-ARS), a Phase 2/3 program for hospitalized COVID-19, and an ongoing Phase 2 study in prostate cancer in combination with Bayer's darolutamide; (ii). (ABC294640) 是一款首创的口服选择性鞘氨醇激酶-2（SPHK2）抑制剂，具有抗炎、抗病毒、代谢调节和抗癌活性，针对多种适应症，并与美国政府及学术界合作开发医疗对策，包括用于埃博拉病毒病、辐射暴露相关适应症（如胃肠道急性辐射综合征 [GI-ARS]）、针对住院 COVID-19 患者的 2/3 期临床项目，以及正在进行的与拜耳公司达罗他胺联合治疗前列腺癌的 2 期研究；(ii) 。RHB-102 RHB-102(Bekinda®), with a planned Phase 2 proof-of-concept study for (Bekinda®)，并计划开展一项2期概念验证研究GLP-1 GLP-1/GIP receptor agonist-associated GI intolerance, positive results from a U.S. Phase 3 study for acute gastroenteritis and gastritis, positive results from a U.S. Phase 2 study forIBS-D and potential UK submission for chemotherapy and radiotherapy induced nausea and vomiting. RHB-102 is partnered with Hyloris Pharmaceuticals (EBR: HYL) for worldwide development and commercialization outside North America; (iii). /GIP受体激动剂相关的胃肠道不耐受，美国急性胃肠炎和胃炎III期临床试验取得阳性结果，美国IBS-D（腹泻型肠易激综合征）II期临床试验取得阳性结果，以及针对化疗和放疗引起的恶心和呕吐可能在英国提交上市申请。RHB-102已与Hyloris Pharmaceuticals（EBR: HYL）合作，负责北美以外地区的全球开发和商业化；(iii) 。RHB-204 RHB-204, a next-generation optimized formulation of RHB-104, with aplanned Phase 2 study for Crohn's disease (based on RHB-104's positive Phase 3 Crohn's disease study results); and (iv) ，RHB-104的下一代优化配方，计划开展针对克罗恩病的2期临床研究（基于RHB-104在克罗恩病3期临床研究中取得的阳性结果）；以及（iv）RHB-107 RHB-107(upamostat), an oral broad-acting, host-directed,serine protease inhibitor with potential for pandemic preparedness, including COVID-19 and also targeting multiple cancer and inflammatory gastrointestinal diseases. (upamostat)，一种口服、广谱、宿主导向的丝氨酸蛋白酶抑制剂，具备大流行病防范潜力，包括针对COVID-19，同时也靶向多种癌症和炎症性胃肠道疾病。More information about the Company is available at 有关本公司的更多信息，请访问www.redhillbio.com www.redhillbio.com/ /X.com/RedHillBio X.com/RedHillBio. 。Forward Looking Statements 前瞻性陈述This press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995 and may discuss investment opportunities, stock analysis, financial performance, investor relations, and market trends. Such statements may be preceded by the words 'intends,' 'may,' 'will,' 'plans,' 'expects,' 'anticipates,' 'projects,' 'predicts,' 'estimates,' 'aims,' 'believes,' 'hopes,' 'potential' or similar words and include, among others, the consummation of the offering and the satisfaction of customary closing conditions related to the offering, the use of proceeds therefrom, the potential exercise of the series warrants and potential proceeds therefrom, potential acquisition of strategic products, statements regarding the potential submission of Talicia® for UK Marketing Authorisation and any approval thereof and statements regarding the potential effects of Talicia® in the treatment of Helicobacter pylori infection. 本新闻稿包含经1995年《私人证券诉讼改革法案》界定的“前瞻性陈述”，并可能涉及投资机会、股票分析、财务表现、投资者关系以及市场趋势。此类陈述之前可能出现“打算”、“可能”、“将”、“计划”、“预期”、“预计”、“规划”、“预测”、“估计”、“旨在”、“相信”、“希望”、“潜在”或类似词语，并包括但不限于：发行的完成及与发行相关的惯例交割条件的满足、所得款项的用途、系列权证的潜在行权及其潜在收益、战略性产品的潜在收购、关于Talicia®在英国上市许可申请的潜在提交及任何相关批准的陈述，以及关于Talicia®在治疗幽门螺杆菌感染方面潜在影响的陈述。Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control and cannot be predicted or quantified, and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. 前瞻性陈述基于某些假设，并受各种已知和未知的风险与不确定性的影响，其中许多超出本公司的控制范围且无法预测或量化，因此实际结果可能与这些前瞻性陈述所明示或暗示的结果存在重大差异。Such risks and uncertainties include, without limitation: market and other conditions, the risk that the MAA submission for Talicia may not be approved; the risk that the Company will not succeed in its enforcement action against Kukbo, and if successful may not recover all or any of awards granted by the New York Supreme Court; the risk that opaganib does not receive a priority review voucher, marketing exclusivity or accelerated development and review times; the risk that opaganib is. 此类风险和不确定性包括但不限于：市场及其他条件；Talicia的上市许可申请（MAA）可能无法获得批准的风险；公司针对Kukbo采取的强制执行行动可能无法成功，且即使成功也可能无法收回纽约最高法院授予的全部或部分裁决金额的风险；opaganib可能无法获得优先审评券、市场独占权或加速开发和审评时间的风险；opaganib是……的风险。GLP-1 胰高血糖素样肽-1/GIP-related nausea, vomiting and diarrhea; the risk regarding the Company's ability to regain and maintain compliance with Nasdaq's listing requirements, including the minimum bid price requirement; the risk that the addition of new revenue generating products or out-licensing transactions will not occur; the risk that the Company will not receive future milestone payments under its existing agreements or that they will be less than anticipated; the risk of current uncertainty regarding U.S. /与GIP相关的恶心、呕吐和腹泻；公司恢复并维持符合纳斯达克上市要求（包括最低出价要求）的能力相关风险；新增创收产品或对外许可交易未能实现的风险；公司无法根据现有协议收到未来里程碑付款，或收到的款项低于预期的风险；当前美国方面的不确定性风险government research and development funding and that the U.S. government is under no obligation to continue to support development of our products and can cease such support at any time; the risk that acceptance onto the RNCP Product Development Pipeline or other governmental and non-governmental development programs will not guarantee ongoing development or that any such development will not be completed or successful; the risk that the FDA does not agree with the Company's proposed development plans for its programs; the risk that the Company's development programs and studies may not be successful and, even if successful, such studies and results may not be sufficient for regulatory applications, including emergency use or marketing applications, and that additional studies may be required; the risk that the Company will not successfully commercialize its products; as well as risks and uncertainties associated with (i) the initiation, timing, progress and results of the Company's research, manufacturing, pre-clinical studies, clinical trials, and other therapeutic candidate development efforts, and the timing of the commercial launch of its commercial products and ones it may acquire or develop in the future; (ii) the Company's ability to advance its therapeutic candidates into . 政府研发资金，且美国政府没有义务继续支持我们产品的开发，并可以随时终止此类支持；进入RNCP产品开发管道或其他政府和非政府开发项目并不能保证持续开发，也不能保证任何此类开发能够完成或取得成功；FDA可能不同意公司为其项目提出的开发计划；公司的开发项目和研究可能不会成功，即使成功，这些研究和结果也可能不足以支持监管申请（包括紧急使用或上市申请），并且可能需要额外的研究；公司可能无法成功将其产品商业化；以及与以下方面相关的风险和不确定性：(i) 公司研究、生产、临床前研究、临床试验及其他治疗候选产品开发工作的启动、时机、进展和结果，以及其现有产品及未来可能收购或开发的产品的商业上市时机；(ii) 公司推进其治疗候选产品进入的能力。Category: Financials 类别：金融[1] [1]Talicia 塔利西亚® ®(omeprazole magnesium, amoxicillin and rifabutin) is indicated for the treatment of （奥美拉唑镁、阿莫西林和利福布汀）适用于治疗H. pylori 幽门螺杆菌infection in adults. For full prescribing information see: 成人感染。完整处方信息请参见：www.Talicia.com www.Talicia.com. 。Logo - 标志 -https://mma.prnewswire.com/media/1334141/5268648/RedHill_Biopharma_Logo.jpg https://mma.prnewswire.com/media/1334141/5268648/RedHill_Biopharma_Logo.jpgCompany contact: 公司联系人：Adi Frish 阿迪·弗里什Chief Corporate & Business Development Officer 首席企业与业务发展官RedHill Biopharma 红山生物制药[emailprotected] [emailprotected]SOURCE RedHill Biopharma Ltd. 来源：RedHill Biopharma Ltd.21 二十一% %more press release views with 更多新闻稿浏览量，借助Request a Demo 申请演示

$6 million upfront with up to approximately $13.4 million of potential aggregate gross proceeds upon the exercise in full of warrants TEL AVIV, Israel & RALEIGH, N.C., June 18, 2026 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 8,571,429 American Depositary Shares ("ADSs") (or ADS equivalents in lieu thereof), each ADS representing ten thousand (10,000) ordinary shares of the Company, series A-1 warrants to purchase up to an aggregate of 8,571,429 ADSs and series A-2 warrants to purchase up to an aggregate of 8,571,429 ADSs, at a combined purchase price of $0.70 per ADS (or ADS equivalent in lieu thereof) and accompanying warrants in a private placement. The Series A-1 warrants have an exercise price of $0.86 per ADS, are exercisable immediately and have a term of five years following the Effectiveness Date (as defined below), and the Series A-2 warrants have an exercise price of $0.70 per ADS, are exercisable immediately and have a term of 18 months following the Effectiveness Date. The private placement is expected to close on June 22, 2026, subject to the satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The gross proceeds to the Company from this offering are expected to be approximately $6 million, before deducting the placement agent's fees and other offering expenses payable by the Company. The potential additional gross proceeds to the Company from the series A-1 warrants and the series A-2 warrants, if fully exercised on a cash basis, will be approximately $13.4 million. No assurance can be given that any of the series warrants will be exercised, or that the Company will receive cash proceeds from the exercise of the series warrants. The Company intends to use a portion of the net proceeds to support a potential strategic product acquisition and the balance for working capital, research and development and general corporate purposes. No definitive acquisition agreement has been executed, and any such transaction would remain subject to completion of definitive documentation, financing and other customary conditions. There can be no assurance that any such transaction will be completed. The securities described above were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"), and/or Regulation D promulgated thereunder and, along with the ordinary shares of the Company represented by ADSs underlying the warrants, have not been registered under the Securities Act or applicable state securities laws. Accordingly, the securities issued in the private placement and ordinary shares of the Company represented by ADSs underlying the warrants may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. Pursuant to a registration rights agreement with the investors, the Company has agreed to file a resale registration statement covering the securities described above (such date of effectiveness of the resale registration statement, the "Effectiveness Date"). This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. About RedHill Biopharma RedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company primarily focused on U.S. development and commercialization of drugs for gastrointestinal diseases, infectious diseases and oncology. RedHill promotes the FDA-approved gastrointestinal drug Talicia ®, for the treatment of Helicobacter pylori (H. pylori) infection in adults[1], with a U.S. co-commercialization agreement with Cumberland Pharmaceuticals (Nasdaq: CPIX). RedHill's key clinical late-stage development programs include: (i) opaganib (ABC294640), a first-in-class, orally administered sphingosine kinase-2 (SPHK2) selective inhibitor with anti-inflammatory, antiviral, metabolic and anticancer activity, targeting multiple indications with U.S. government and academic collaborations intended for medical countermeasure development including for Ebola virus disease, radiation exposure indications such as GI-Acute Radiation Syndrome (GI-ARS), a Phase 2/3 program for hospitalized COVID-19, and an ongoing Phase 2 study in prostate cancer in combination with Bayer's darolutamide; (ii) RHB-102 (Bekinda®), with a planned Phase 2 proof-of-concept study for GLP-1/GIP receptor agonist-associated GI intolerance, positive results from a U.S. Phase 3 study for acute gastroenteritis and gastritis, positive results from a U.S. Phase 2 study for IBS-D and potential UK submission for chemotherapy and radiotherapy induced nausea and vomiting. RHB-102 is partnered with Hyloris Pharmaceuticals (EBR: HYL) for worldwide development and commercialization outside North America; (iii) RHB-204, a next-generation optimized formulation of RHB-104, with a planned Phase 2 study for Crohn's disease (based on RHB-104's positive Phase 3 Crohn's disease study results); and (iv) RHB-107 (upamostat), an oral broad-acting, host-directed, serine protease inhibitor with potential for pandemic preparedness, including COVID-19 and also targeting multiple cancer and inflammatory gastrointestinal diseases. More information about the Company is available at / X.com/RedHillBio. Forward Looking Statements This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and may discuss investment opportunities, stock analysis, financial performance, investor relations, and market trends. Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words and include, among others, the consummation of the offering and the satisfaction of customary closing conditions related to the offering, the use of proceeds therefrom, the potential exercise of the series warrants and potential proceeds therefrom, potential acquisition of strategic products, statements regarding the potential submission of Talicia® for UK Marketing Authorisation and any approval thereof and statements regarding the potential effects of Talicia® in the treatment of Helicobacter pylori infection. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control and cannot be predicted or quantified, and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation: market and other conditions, the risk that the MAA submission for Talicia may not be approved; the risk that the Company will not succeed in its enforcement action against Kukbo, and if successful may not recover all or any of awards granted by the New York Supreme Court; the risk that opaganib does not receive a priority review voucher, marketing exclusivity or accelerated development and review times; the risk that opaganib is not accepted into Ebola virus disease control programs, or if accepted, that it does not demonstrate efficacy; the risk that development of RHB-204 for Crohn's disease may not be completed, or if completed may not be approved or may not achieve commercial success; the risk that opaganib is not effective against the indications for which we develop our products; the risk that RHB-102 (Bekinda) does not effectively reduce GLP-1/GIP-related nausea, vomiting and diarrhea; the risk regarding the Company's ability to regain and maintain compliance with Nasdaq's listing requirements, including the minimum bid price requirement; the risk that the addition of new revenue generating products or out-licensing transactions will not occur; the risk that the Company will not receive future milestone payments under its existing agreements or that they will be less than anticipated; the risk of current uncertainty regarding U.S. government research and development funding and that the U.S. government is under no obligation to continue to support development of our products and can cease such support at any time; the risk that acceptance onto the RNCP Product Development Pipeline or other governmental and non-governmental development programs will not guarantee ongoing development or that any such development will not be completed or successful; the risk that the FDA does not agree with the Company's proposed development plans for its programs; the risk that the Company's development programs and studies may not be successful and, even if successful, such studies and results may not be sufficient for regulatory applications, including emergency use or marketing applications, and that additional studies may be required; the risk that the Company will not successfully commercialize its products; as well as risks and uncertainties associated with (i) the initiation, timing, progress and results of the Company's research, manufacturing, pre-clinical studies, clinical trials, and other therapeutic candidate development efforts, and the timing of the commercial launch of its commercial products and ones it may acquire or develop in the future; (ii) the Company's ability to advance its therapeutic candidates into clinical trials or to successfully complete its pre-clinical studies or clinical trials or the development of any necessary commercial companion diagnostics; (iii) the extent and number and type of additional studies that the Company may be required to conduct and the Company's receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings, approvals and feedback; (iv) the manufacturing, clinical development, commercialization, and market acceptance of the Company's therapeutic candidates and Talicia; (v) the Company's ability to successfully commercialize and promote Talicia; (vi) the Company's ability to establish and maintain corporate collaborations; (vii) the Company's ability to acquire products approved for marketing in the U.S. that achieve commercial success and build its own marketing and commercialization capabilities; (viii) the interpretation of the properties and characteristics of the Company's therapeutic candidates and the results obtained with its therapeutic candidates in research, pre-clinical studies or clinical trials; (ix) the implementation of the Company's business model, strategic plans for its business and therapeutic candidates; (x) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; (xi) parties from whom the Company licenses its intellectual property defaulting in their obligations to the Company; (xii) the Company's ability to collect on its judgment against Kukbo; (xiii) estimates of the Company's expenses, future revenues, capital requirements and needs for additional financing; (xiv) the effect of patients suffering adverse experiences using investigative drugs under the Company's Expanded Access Program; (xv) competition from other companies and technologies within the Company's industry; and (xvi) the hiring and employment commencement date of executive managers. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 20-F filed with the SEC on April 27, 2026. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement, whether as a result of new information, future events or otherwise unless required by law. Category: Financials [1]Talicia® (omeprazole magnesium, amoxicillin and rifabutin) is indicated for the treatment of H. pylori infection in adults. For full prescribing information see: . Logo - Company contact: Adi Frish Chief Corporate & Business Development Officer RedHill Biopharma [email protected] SOURCE RedHill Biopharma Ltd. 21% more press release views with Request a Demo